NASDAQ:OCUL

Ocular Therapeutix Competitors

$16.50
+0.61 (+3.84 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.05
Now: $16.50
$17.00
50-Day Range
$15.82
MA: $18.26
$20.84
52-Week Range
$4.76
Now: $16.50
$24.30
Volume1.09 million shs
Average Volume938,552 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.29

Competitors

Ocular Therapeutix (NASDAQ:OCUL) Vs. BHVN, AVIR, SAGE, HCM, ARNA, and EBS

Should you be buying OCUL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Ocular Therapeutix, including Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Arena Pharmaceuticals (ARNA), and Emergent BioSolutions (EBS).

Biohaven Pharmaceutical (NYSE:BHVN) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 52.5% of Ocular Therapeutix shares are held by institutional investors. 19.1% of Biohaven Pharmaceutical shares are held by company insiders. Comparatively, 7.7% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Biohaven Pharmaceutical and Ocular Therapeutix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical021002.83
Ocular Therapeutix01213.00

Biohaven Pharmaceutical currently has a consensus target price of $96.4545, suggesting a potential upside of 28.95%. Ocular Therapeutix has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Biohaven Pharmaceutical.

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 2.29, suggesting that its stock price is 129% more volatile than the S&P 500.

Profitability

This table compares Biohaven Pharmaceutical and Ocular Therapeutix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Ocular Therapeutix-780.19%-14,065.71%-81.81%

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Ocular Therapeutix's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.86
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21

Ocular Therapeutix has higher revenue and earnings than Biohaven Pharmaceutical. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Biohaven Pharmaceutical on 8 of the 14 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Atea Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Atea Pharmaceuticals00403.00

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Atea Pharmaceuticals has a consensus target price of $69.3333, suggesting a potential upside of 27.03%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Atea Pharmaceuticals.

Profitability

This table compares Ocular Therapeutix and Atea Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Atea PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Ocular Therapeutix and Atea Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21
Atea PharmaceuticalsN/AN/AN/AN/AN/A

Atea Pharmaceuticals has lower revenue, but higher earnings than Ocular Therapeutix.

Summary

Ocular Therapeutix beats Atea Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Sage Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Sage Therapeutics08802.50

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Sage Therapeutics has a consensus target price of $87.0625, suggesting a potential upside of 15.06%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Sage Therapeutics.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Earnings & Valuation

This table compares Ocular Therapeutix and Sage Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21
Sage Therapeutics$6.87 million643.05$-680,240,000.00($13.38)-5.66

Ocular Therapeutix has higher earnings, but lower revenue than Sage Therapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Sage Therapeutics on 9 of the 15 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Hutchison China MediTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Hutchison China MediTech00203.00

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Hutchison China MediTech has a consensus target price of $40.00, suggesting a potential upside of 37.03%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Hutchison China MediTech.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Hutchison China MediTech has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Hutchison China MediTechN/AN/AN/A

Earnings & Valuation

This table compares Ocular Therapeutix and Hutchison China MediTech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21
Hutchison China MediTech$204.89 million20.74$-106,020,000.00($0.80)-36.49

Ocular Therapeutix has higher earnings, but lower revenue than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Summary

Ocular Therapeutix beats Hutchison China MediTech on 8 of the 13 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Arena Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Arena Pharmaceuticals001503.00

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Arena Pharmaceuticals has a consensus target price of $92.80, suggesting a potential upside of 37.20%. Given Ocular Therapeutix's higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Arena Pharmaceuticals.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Ocular Therapeutix and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Arena PharmaceuticalsN/A-33.17%-30.41%

Earnings & Valuation

This table compares Ocular Therapeutix and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21
Arena Pharmaceuticals$806.43 million5.06$397.55 million$7.698.80

Arena Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Ocular Therapeutix on 8 of the 14 factors compared between the two stocks.

Ocular Therapeutix (NASDAQ:OCUL) and Emergent BioSolutions (NYSE:EBS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Ocular Therapeutix and Emergent BioSolutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ocular Therapeutix-780.19%-14,065.71%-81.81%
Emergent BioSolutions12.50%26.68%12.70%

Earnings & Valuation

This table compares Ocular Therapeutix and Emergent BioSolutions' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$4.23 million296.73$-86,370,000.00($2.01)-8.21
Emergent BioSolutions$1.11 billion3.59$54.50 million$2.9125.59

Emergent BioSolutions has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ocular Therapeutix has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Institutional & Insider Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 80.2% of Emergent BioSolutions shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by insiders. Comparatively, 14.1% of Emergent BioSolutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ocular Therapeutix and Emergent BioSolutions, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocular Therapeutix01213.00
Emergent BioSolutions02502.71

Ocular Therapeutix presently has a consensus target price of $24.80, suggesting a potential upside of 50.30%. Emergent BioSolutions has a consensus target price of $113.6667, suggesting a potential upside of 52.63%. Given Emergent BioSolutions' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Ocular Therapeutix.

Summary

Emergent BioSolutions beats Ocular Therapeutix on 11 of the 15 factors compared between the two stocks.


Ocular Therapeutix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80+2.7%$4.64 billionN/A-6.10Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.58+4.8%$4.52 billionN/A0.00Analyst Report
Increase in Short Interest
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.67+4.9%$4.42 billion$6.87 million-7.31Analyst Report
Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19+1.5%$4.25 billion$204.89 million-36.49
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64+1.8%$4.08 billion$806.43 million-9.58Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+2.3%$3.97 billion$1.11 billion23.95Analyst Report
I-Mab logo
IMAB
I-Mab
1.4$55.09+9.9%$3.96 billion$4.31 million-1.91Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90+1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36+2.4%$3.71 billion$117.91 million-10.82
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.48+5.0%$3.58 billionN/A-5.99
LEGN
Legend Biotech
1.2$26.76+1.1%$3.53 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14+2.4%$3.49 billion$114.62 million-7.72Analyst Report
Insmed logo
INSM
Insmed
1.2$33.02+4.1%$3.41 billion$136.47 million-12.70
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.41 billion$339.08 million-12.37Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.37 billion$306.98 million-6.85
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34+0.3%$3.30 billion$36.13 million-70.66Unusual Options Activity
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75+3.7%$3.25 billion$26.52 million-7.91
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.44+3.8%$3.12 billionN/A-57.43Insider Selling
News Coverage
Arvinas logo
ARVN
Arvinas
1.5$62.89+2.5%$3.07 billion$42.98 million-24.57
Alkermes logo
ALKS
Alkermes
1.2$19.23+1.9%$3.06 billion$1.17 billion-41.80
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43+1.7%$3.05 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69+1.5%$2.99 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
OPKO Health logo
OPK
OPKO Health
1.9$4.21+1.9%$2.82 billion$901.90 million-23.36
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.80 billion$260.98 million-365.00
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.79 billion$644.77 million-10.39
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95+2.9%$2.69 billion$306.49 million25.79
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53+3.4%$2.69 billionN/A-23.92
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.96+5.5%$2.65 billion$25 million-9.19Insider Selling
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.61 billion$60,000.00-10.02
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.47+3.1%$2.58 billion$2.11 million-8.98Analyst Report
News Coverage
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$151.03+2.7%$2.51 billion$120.28 million-152.56Analyst Report
Decrease in Short Interest
News Coverage
Xencor logo
XNCR
Xencor
1.0$43.17+6.9%$2.50 billion$156.70 million-30.84News Coverage
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.80+4.5%$2.40 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64+1.3%$2.36 billion$33.94 million-89.03
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21+2.3%$2.35 billion$15 million-17.39Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81+0.5%$2.18 billion$963.01 million13.61
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.83+3.6%$2.12 billion$23.90 million-17.29Analyst Report
Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.17+1.3%$2.01 billion$410,000.00-6.12Analyst Report
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.11+0.6%$2.01 billion$429.76 million-102.18
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.55+3.4%$2.00 billionN/A-19.91
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.80+5.3%$1.98 billion$103.54 million-19.40Insider Selling
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93+2.6%$1.96 billionN/A-27.20Increase in Short Interest
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$120.94+4.4%$1.94 billionN/A-10.93
Kura Oncology logo
KURA
Kura Oncology
1.6$29.20+5.8%$1.93 billionN/A-17.91
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$47.01+2.9%$1.93 billionN/A0.00Analyst Report
Insider Selling
High Trading Volume
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.65+1.7%$1.89 billion$34.51 million-17.65
MacroGenics logo
MGNX
MacroGenics
1.2$31.28+5.5%$1.88 billion$64.19 million-9.99Decrease in Short Interest
MORF
Morphic
1.3$55.98+3.0%$1.82 billion$16.98 million-35.88Insider Selling
Decrease in Short Interest
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.